LabyRx Immuno-Oncology
- Biotech or pharma, therapeutic R&D
Clinical-stage immuno-oncology company. Platforms: 1) Cancer treatment vaccine for 40% of all cancers (adenocarcinomas) in Phase II 2) Antibody-based treatments and diagnostics in pre-clinical stage.
Results of our clinical trial has warranted US FDA application as a "Breakthrough Vaccine". Seeking Series A round; open to M&A, IP acquisition or collaborative development (e.g., CAR-T/M, antibodies, etc.) as a true joint venture (not contract work).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}